Clinical trial

A Study to Evaluate Effects of KN056 in Healthy Participants

NCT05385575

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2022-08-09

PhasePHASE1

Study timeline

Study start (actual)2022-08-09Date precision: day

Registry last updated2024-12-30

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Type 2 Diabetesunresolved

Interventions

KN056 (0.1mg)DRUG

KN056 (0.3mg)DRUG

KN056 (1.0mg)DRUG

KN056 (3.0mg)DRUG

KN056 (6.0mg)DRUG

KN056 (12.0mg)DRUG

KN056 (18.0mg)DRUG

Sponsors & collaborators

Suzhou Alphamab Co., Ltd.lead sponsor

Novotech (Australia) Pty Limitedcollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05385575 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.